Key insights
- Genmab's Q1 revenue increased 25% YoY, driven by royalties from DARZALEX (marketed by JNJ) and Kesimpta (marketed by Novartis). This indicates continued strong performance for these drugs, which could positively influence JNJ's and Novartis' future earnings and investor sentiment, indirectly benefiting the broader US equity market.
Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.
Revenue for the three months ended March 31 rose to $896 million from $715 million a year earlier, while royalty revenue climbed 26% to $742 million. The company said growth was primarily fueled by higher sales of DARZALEX, marketed by Johnson & Johnson, and Kesimpta, marketed by Novartis.